or Try an Advanced Search...

    Technical Analysis for MRUS - Merus N.V.

    Grade Last Price % Change Price Change
    C 44.93 -0.63% -0.29
    MRUS closed up 0.98 percent on Wednesday, May 15, 2024, on 1.15 times normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical MRUS trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish -0.63%
    Inside Day Range Contraction -0.63%
    Gapped Up Strength -0.63%
    MACD Bearish Signal Line Cross Bearish 0.35%
    50 DMA Support Bullish 0.35%
    Outside Day Range Expansion 0.35%
    Crossed Above 50 DMA Bullish -2.02%
    Gapped Up Strength -2.02%
    Fell Below 50 DMA Bearish 0.91%
    20 DMA Support Bullish 0.91%
    Older End-of-Day Signals for MRUS ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 1 hour ago
    Fell Below 20 DMA about 1 hour ago
    20 DMA Support about 1 hour ago
    50 DMA Support about 1 hour ago
    Fell Below Previous Day's Low about 1 hour ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    MRUS Chart by TradingView
    Basic chart:

    Profile

    Merus N.V. Description

    Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome

    Is MRUS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 13 Merus gets FDA breakthrough therapy status for petosemtamab
    May 13 Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
    May 11 Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
    May 10 Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame
    May 9 Merus GAAP EPS of -$0.59 beats by $0.20, revenue of $7.89M misses by $0.45M
    May 8 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
    May 6 FDA accepts Merus application for Zeno for lung, pancreatic cancer
    May 6 Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
    Apr 29 Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
    Apr 26 Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
    See more MRUS news...

    Comments

    S

    SwingScalp about 1 year ago

    This is the only Expansion Breakout scan symbol for March 15th.  Looks interesting to me so might take this setup today.

    0 Reply
    T

    TraderMike about 1 year ago

    I hope it goes well

    0 Reply
    S

    SwingScalp about 1 year ago

    I added several Expansion Pivot Buy scan result symbols from the 15th to my daytrade charts in my broker platform as well.  Thanks.  ROL VERX and TIMB look interesting.

    0 Reply
    S

    SwingScalp about 1 year ago

    I should have written the only Bullish - Expansion Breakout scan symbol.

    0 Reply
    View full discussion...

    Indicators

    Indicator Value
    52 Week High 52.035
    52 Week Low 19.805
    Average Volume 640,682
    200-Day Moving Average 32.01
    50-Day Moving Average 44.64
    20-Day Moving Average 44.75
    10-Day Moving Average 46.45
    Average True Range 2.01
    RSI (14) 51.22
    ADX 21.38
    +DI 21.04
    -DI 17.08
    Chandelier Exit (Long, 3 ATRs) 43.47
    Chandelier Exit (Short, 3 ATRs) 45.30
    Upper Bollinger Bands 50.04
    Lower Bollinger Band 39.46
    Percent B (%b) 0.54
    BandWidth 23.65
    MACD Line 0.56
    MACD Signal Line 0.66
    MACD Histogram -0.0999
    Fundamentals Value
    Market Cap 2.61 Billion
    Num Shares 57.7 Million
    EPS -3.72
    Price-to-Earnings (P/E) Ratio -12.15
    Price-to-Sales 52.88
    Price-to-Book 6.02
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 47.25
    Resistance 3 (R3) 47.32 46.71 46.91
    Resistance 2 (R2) 46.71 46.19 46.68 46.80
    Resistance 1 (R1) 45.96 45.87 45.66 45.89 46.68
    Pivot Point 45.35 45.35 45.20 45.32 45.35
    Support 1 (S1) 44.60 44.83 44.30 44.53 43.74
    Support 2 (S2) 43.99 44.51 43.96 43.62
    Support 3 (S3) 43.24 43.99 43.51
    Support 4 (S4) 43.17